Related Experiment Video
Updated: Apr 6, 2026
11:35
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
58.9K
Clinical decision-making in multiple sclerosis: Challenges reported internationally with emerging treatment
Pamela Ng1, Suzanne Murray1, Sean M Hayes1
1AXDEV Group Inc., 210-8, Place du Commerce, Brossard, QC, Canada J4W 3H2.
Multiple Sclerosis and Related Disorders
|July 22, 2015
Summary
Healthcare providers face challenges with new Multiple Sclerosis (MS) treatments, including safety, screening, and monitoring. Further education and policy changes are needed to improve clinical decision-making for MS therapies.
Area of Science:
- Neurology
- Pharmacology
- Healthcare Management
Background:
- Multiple Sclerosis (MS) treatment landscape evolving with new disease-modifying therapies (DMTs).
- MS healthcare providers require comprehensive understanding of new DMTs for optimal patient care.
- International study identifies challenges faced by neurologists and nurses in managing MS patients with new therapies.
Purpose of the Study:
- To understand issues and challenges in MS treatment and management by neurologists and nurses.
- To gather evidence for Continuing Medical Education (CME) initiatives and health policies.
- To focus on challenges related to newly approved therapies, their risks, and necessary precautions.
Main Methods:
- Exploratory study and literature review informed survey design.
- IRB-approved online survey deployed to MS Neurologists and Nurses.
- International participation across 6 countries (Germany, France, Italy, Spain, UK, USA).
Main Results:
- Sample included 156 Neurologists and 153 Nurses.
- Substantive challenges reported in knowledge and confidence regarding safety profiles of new DMTs.
- Difficulties identified in screening patients and monitoring for serious adverse events associated with new MS therapies.
Conclusions:
- International healthcare providers report significant challenges integrating new MS therapies into practice.
- Study highlights factors contributing to these challenges.
- Identifies targets for CME and policy interventions to improve clinical decision-making in MS care.
Related Concept Videos
01:15Methods of Documentation VI: Case Management Model
1.0K
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
For example, a patient with a chronic...
1.0K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
72
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72
01:20Decision Making
1.2K
Decision-making is a fundamental cognitive process that involves evaluating alternatives and selecting among them. This process can range from simple choices, such as deciding what to wear, to complex decisions, like choosing a major in college or a career path. The complexity of the decision often dictates the approach we use, which can be broadly categorized into two types: automatic and controlled decision-making.
Automatic decision-making is fast, intuitive, and relies on gut feelings...
Automatic decision-making is fast, intuitive, and relies on gut feelings...
1.2K
01:29Therapeutic Drug Monitoring: Affecting Factors
349
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
349